Adam Bailis

Adam Bailis serves as Professor and Associate Dean of Research at Jefferson College of Health Professions, Thomas Jefferson University, with his office located at 901 Walnut Street, 11th Floor, Philadelphia, PA 19107. His leadership role in research administration complements his active laboratory work in molecular oncology.

Education:

• PhD, Albert Einstein College of Medicine, Bronx, NY (1987)
• PhD Candidate, University of South Carolina, Columbia, SC (1983)
• BA, University of Delaware, Newark, DE (1982)

Dr. Bailis's research centers on genome instability mechanisms including mutations, loss of heterozygosity, and chromosomal rearrangements in tumorigenesis. His laboratory pioneered studies on homology directed repair (HDR) with focus on BRCA1/BRCA2 tumor suppressors and RAD52 synthetic lethality. Utilizing budding yeast models, his team develops high-throughput screening for RAD52 inhibitors to create targeted cancer therapies that spare healthy tissue. This work bridges fundamental DNA repair biology with translational oncology applications.

His publication portfolio demonstrates consistent focus on homologous recombination pathways across model systems and human cancers, particularly examining RAD52/RAD59 variants in breast cancer susceptibility and therapeutic response. Research spans molecular genetics, cancer disparities, and drug discovery with emphasis on African-American populations and BRCA-deficient cancers.

Scientific Awards:

• Irell & Manella Graduate School of Biological Sciences Excellence in Teaching Award (2003)
• Irell & Manella Graduate School of Biological Sciences Excellence in Teaching Award (2002)
• Taber Outstanding Graduate Student Award (1982)
• Degree with Honors and Distinction (1982)

While specific advisees and grant funding details are not provided in the source material, Dr. Bailis's teaching awards indicate significant mentorship contributions. His laboratory maintains active research in DNA repair mechanisms with therapeutic development as the primary translational objective.

He directs a research laboratory investigating genome stability using yeast genetics to model human DNA repair pathways, with current emphasis on developing RAD52-targeted chemotherapeutics for precision oncology applications.